Antimicrobial resistance

Global Health Leaders Unite to Confront Urgent Public Health Crisis of Antimicrobial Resistance

Retrieved on: 
Tuesday, May 7, 2024
Public Policy, Government, Other Communications, General Health, Health, Other Policy Issues, Infectious Diseases, Communications, Public, Cancer, Antimicrobial resistance, Social isolation, Pathogenic bacteria, Risk, Malaria, CDC, Animal, AMR, Death, Biotechnology Innovation Organization, Parent, Research, BIO, Plant, Friends, Environment, Human, Partnership, Disease, Family, JD, Patient, Caregiver, Face, Diary, Child, HIV, Infection, Associate, TB, COVID-19, Diplomatic rank, Pharmaceutical industry

Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.

Key Points: 
  • Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.
  • "Antimicrobial resistance is an urgent global public health threat that poses risks to modern medicine, the health of humans, animals, plants, the environment, and the global economy.
  • These stories are poised to transform the AMR crisis from a distant concept to a relatable and urgent reality.
  • Putting a human face on this global emergency is critical to motivating action that can change the course of this escalating health crisis.

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Retrieved on: 
Thursday, May 2, 2024
Technology, Medical Devices, Medical Supplies, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Artificial Intelligence, AbCellera, CFO, University, Cancer, SoftBank Vision Fund, Antimicrobial resistance, Bone marrow, HBM, Pneumonia, Head, Risk, Hospital, Metagenomics, Infection, Survival, AMR, Public, Eli Lilly, Khosla Ventures, Partnership, University of California, Research, Artificial intelligence, DNA, Partner (business rank), Transplant, Patient, Immunodeficiency, Eric Schmidt, General partnership, MD Anderson Cancer Center, Death, Growth, Pharmaceutical industry

Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.

Key Points: 
  • Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.
  • The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare.
  • The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting.
  • Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases.

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Retrieved on: 
Monday, April 22, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Urinary tract infection, Pyelonephritis, WHO, News, World Health Organization, Safety, Infection, European Commission, Bacteria, Inc., AMR, Aztreonam, HAP, Fungal infection, VAP, Hospital-acquired pneumonia, Gram-negative bacteria, Patient, PFE, Ventilator-associated pneumonia, Parasitism, Multiple drug resistance, Virus, Civil service commission, Fungus, Antimicrobial resistance, Head, Disease, Gram, Vaccine

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
  • It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
  • “For healthcare teams treating patients with serious Gram-negative bacterial infections, the prospect of running out of effective treatment options is a daunting but very real threat,” said Yehuda Carmeli, Head, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, Israel, and an investigator in the REVISIT study.
  • Marketing authorization applications for EMBLAVEO are planned for submission in other countries.

NASA Science, Hardware Aboard SpaceX's 30th Resupply Launch to Station

Retrieved on: 
Thursday, March 21, 2024
Falcon 9, Biotechnology, Artemis, Antimicrobial resistance, Gateway, Light, International Space Station, Astrobee, 3D, EDT, Television, Spacecraft, Biology, Moon, NASA, Multimedia, SpaceX, NASA TV, Dragon, Communications satellite

SpaceX's Dragon resupply spacecraft, carrying more than 6,000 pounds of cargo to the orbiting laboratory, launched on the company's Falcon 9 rocket at 4:55 p.m. EDT Thursday, from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida.

Key Points: 
  • SpaceX's Dragon resupply spacecraft, carrying more than 6,000 pounds of cargo to the orbiting laboratory, launched on the company's Falcon 9 rocket at 4:55 p.m. EDT Thursday, from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida.
  • The cargo spacecraft is scheduled to autonomously dock at the space station on Saturday, March 23, at approximately 7:30 a.m. and remain at the orbital outpost for about a month.
  • Live coverage of the arrival will begin at 5:30 a.m. on NASA+, NASA Television, and on the agency's website .
  • Learn more about NASA commercial resupply services missions at:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/nasa-science-hardware-aboard-sp...

Magnolia Medical Technologies Marks World AMR Awareness Week by Recognizing the Need to Reduce Antibiotic Usage through Accurate Blood Culture Results

Retrieved on: 
Monday, November 20, 2023
Select, CDI, Safety, Entrepreneurship, Fungal infection, WHO, AVP, Risk, Government, RN, WAAW, Sepsis, Patient, Infection, Antimalarial medication, Death, Drug resistance, Health, AMR, Invention, Acute kidney injury, Cancer, Diagnosis, Blood culture, Antimicrobial resistance, Hospital, Clostridioides difficile infection, Public, Education, Bloodstream infections, Pharmaceutical industry, Nursing

SEATTLE, Nov. 20, 2023 /PRNewswire/ -- In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

Key Points: 
  • Accurate blood culture results prevent patients from receiving unnecessary, prolonged, and potentially harmful antibiotic therapies, and associated preventable clinical complications, including acute kidney injury, Clostridioides difficile infection (CDI), and multidrug-resistant organism (MDRO) infections.
  • We recently completed a survey of over 1,000 Americans that highlighted the public and medical community's concern with the issue of AMR."
  • Magnolia Medical is encouraging everyone to "Go Blue" from November 18 to 24 to raise awareness for AMR and the need for continued education of this issue.
  • Please visit VoicesofSepsis.org to encourage action from your congressional representatives to support patient safety measures that also help combat the threat of AMR.

Pharma Leader Dr. Holger Zimmermann Joins Lysando's Advisory Board in Pioneering Fight Against Antibiotic-Resistant Bacteria

Retrieved on: 
Wednesday, November 8, 2023
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Knowledge, Hope, Antimicrobial resistance, Advisory board, Pharmaceutical Advertising Advisory Board, Development, Multimedia, Pharmaceutical industry, Vaccine

Lysando, a leading innovator in the fight against antibiotic-resistant bacteria, proudly announces the appointment of Dr. Holger Zimmermann to its Advisory Board.

Key Points: 
  • Lysando, a leading innovator in the fight against antibiotic-resistant bacteria, proudly announces the appointment of Dr. Holger Zimmermann to its Advisory Board.
  • His extensive background in human pharmaceutical pre-clinical and clinical research underscores the transformative potential he brings to Lysando.
  • Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando, expresses his enthusiasm, stating, “We are delighted to welcome Dr. Holger Zimmermann to our Advisory Board.
  • Expressing his excitement to join Lysando, Dr. Holger Zimmermann states, “Lysando's Artilysin® technology represents a powerful tool to combat antibiotic-resistant germs.

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

Retrieved on: 
Tuesday, September 19, 2023
Staphylococcus, MIC, CLSI, Clinical trial, Medical microbiology, Staphylococcus aureus, Patient, Antimicrobial resistance, Clinical and Laboratory Standards Institute, Drug development, Challenge, Campaign, AST, Laboratory, Conference, Clinical, Knee, Peptide, Sosa, Pharmaceutical industry

Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.

Key Points: 
  • Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.
  • She will highlight and discuss various antibiotics in current use and several investigational agents that require a modified AST method, such as the Company’s DLAs.
  • Review and approval of new AST methods by standards development organizations, such as the Clinical and Laboratory Standards Institute (CLSI), is essential.
  • The Company will be presenting two posters describing the initial development of the exebacase MIC method for testing Staphylococci other than Staphylococcus aureus (SoSA) and method verification studies performed to evaluate test performance.

STRONGER ANIMAL WELFARE PROVISIONS KEY TO LOWERING THE USE OF ANTIMICROBIALS IN ANIMAL AGRICULTURE

Retrieved on: 
Tuesday, September 19, 2023
Heart, Human, Infection, Public, Policy, Food safety, Food, AMR, Category, Government, Ventilation, British Columbia Basic Income Expert Panel Report, Animal, Antimicrobial resistance, Risk, European, Federation, Health, Environment, Farm, Disease, Food preservation, Poultry farming, Aquaculture, Renewable energy

TORONTO, Sept. 19, 2023 /CNW/ - A new report from World Animal Protection Canada illustrates the dangers of continued inaction on the overuse of antimicrobials in animal agriculture and the solutions for government and industry.

Key Points: 
  • TORONTO, Sept. 19, 2023 /CNW/ - A new report from World Animal Protection Canada illustrates the dangers of continued inaction on the overuse of antimicrobials in animal agriculture and the solutions for government and industry.
  • Reducing antibiotic use in farming through improvements to animal welfare outlines why the overuse of antimicrobials in animal agriculture is dangerous, and how stronger animal welfare provisions across animal agriculture industries, is key to lowering the use of antimicrobials in Canada.
  • "The reality is if Canada implemented stronger animal welfare policies and infection control provisions in animal agriculture, antimicrobial use could be significantly lessened or even eliminated," said Lynn Kavanagh, World Animal Protection Canada's Farming Campaign Manager.
  • In 2022, the European Union banned prophylactic use of antimicrobials in animal agriculture.

Biosenta announces further advances in research and development of Tri-Filler™

Retrieved on: 
Tuesday, August 8, 2023
Canada, Calcium carbonate, Plastic, University of Calgary, University, Human, CSE, Failure, Paint, COVID-19, Ageing, Gram-negative bacteria, Germ, Global health, Research, AMR, Department of Chemical Engineering, Imperial College London, Carbon, Fungus, CDC, Candida auris, Pseudomonas aeruginosa, Genetically modified bacteria, Chemical substance, Mildew, Antimicrobial resistance, Korea Disease Control and Prevention Agency, Biological engineering, Growth, Calcium hydroxide, Bacteria, Health Canada, Chemical engineering, Virus, Safety, CO2, Environment, Textile, News, Auris, Food preservation, Vaccine, Uranium mining, Microbiology

TORONTO and CALGARY, Alberta, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is pleased to announce further advances in research and development of the Tri-Filler™ particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation.

Key Points: 
  • TORONTO and CALGARY, Alberta, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is pleased to announce further advances in research and development of the Tri-Filler™ particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation.
  • Preliminary testing points to the Tri-Filler™ being effective in inhibiting the growth of both gram-positive and gram-negative bacteria and fungi.
  • Biosenta has identified a number of industry partners with whom Biosenta and the University of Calgary team are in various stages of talks for further research and commercialization.
  • Biosenta Inc., a ground-breaking pioneer in the field of antimicrobial solutions, is on a mission to revolutionize the material world.

Federal, Provincial and Territorial Governments Jointly Release the Pan-Canadian Action Plan on AMR

Retrieved on: 
Thursday, June 22, 2023
Human, Antimicrobial, Action plan, Veterinarian, Public, Infection, Agriculture, AMR, Government, Indigenous peoples, Plant, Death, Animal, Antimicrobial resistance, National Action Plan to Combat Human Trafficking, Council, World Health Organization, Indigenous self-government in Canada, Health, Environment, Potential, Pharmaceutical industry

AMR can spread across geographical borders and between humans, animals, and their shared environments.

Key Points: 
  • AMR can spread across geographical borders and between humans, animals, and their shared environments.
  • Moving forward, the Government of Canada will continue to build on the collaborative work with provincial and territorial governments, Indigenous Peoples, industry stakeholders, and with partners across One Health sectors.
  • Through this Action Plan, together with provinces and territories we can protect the health of humans, animals and the environment against AMR."
  • The Action Plan builds on the 2017 Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action , which was developed in collaboration with federal, provincial and territorial governments.